At the Wells Fargo Healthcare Conference yesterday, Elevance Health’s Chief Financial Officer, Mark Kaye, announced that the company will exit the standalone Medicare Prescription Drug Plan (PDP) market for 2026. Kaye also said Elevance will shift its focus to Medicare Advantage HMO and Dual Special Needs Plans (DSNP). This change in focus is expected to impact about 150,000 current Medicare Advantage members.
Kaye emphasized that Elevance “took a disciplined approach” to the 2026 plan benefits and reaffirmed the company’s outlook for the rest of 2025, noting that it expects to meet previously released financial guidance. Elevance owns Anthem Blue Cross and Blue Shield, WellPoint, Amerigroup, and Carelon Health in the Medicare health market.
What This Means for Agents
Agility will continue to keep you updated as more information becomes available about these changes. Agility provides tools and resources to help Elevance agents communicate with both Medicare Prescription Drug and Medicare Advantage clients in a compliant and effective way.
We strongly recommend building a communication strategy for these members now to reassure your clients and guide them through these upcoming changes at the beginning of October, after they receive their ANOCs. Scott Meeks, Agility’s Medicare Product Specialist, is available to help you develop these strategies and connect you with the best Agility outreach tools.
He can also assist in identifying the best possible Medicare Prescription Drug Plan coverage options for your Elevance PDP clients. You can reach Scott through the Agility Producer Support Team at (866) 590-9771 or support@enrollinsurance.com to schedule a call or meeting with him or to get answers to any insurance questions.
Agility is here to help you stay ahead, support your clients with confidence, and maximize your success this Medicare AEP.
